Purple Biotech - ADR opened lower at $1.46, compared with its previous close of $1.49. In the last trading session, the stock traded between $1.36 and $1.50. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Purple Biotech - ADR is now worth
$ 0.17
Resulting in a loss of
$ 99.83 (99.83%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.02 (+1.34%)
Day High
$1.50
Day Low
$1.36
Day Open
$1.46
Prev Close
$1.49
Volume
65,747
1W Return
28.51%
1M Return
8.63%
3M Return
-2.33%
6M Return
-62.81%
1Y Return
-81.81%
Fundamentals
Market Cap ($ Mn)
2
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-94.68%
EPS (TTM)
$0.00
Investment Returns
1 Week
28.51%
1 Month
8.63%
3 Months
-2.33%
6 Months
-62.81%
9 Months
-74.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
2Sep
Purple Biotech stock rises 22.89% on US patent allowance
Purple Biotech stock rose 22.89% to $2.03 in premarket trading Wednesday. USPTO issued Notice of Allowance for patent covering CAPTN-3 tri-specific antibody constructs. Patent strengthens IP protection for modular architecture enabling rapid development of new candidates. Company plans to start human trials for lead candidate IM1240 in 2027.
2mo ago
7Aug
Purple Biotech corrects Q2 EPS to $(0.41), beats estimate
Purple Biotech revised its Q2 EPS to $(0.41), which beats the $(0.98) consensus by 58.16%. This represents an 89.75% improvement over the prior year's $(4.00) loss.
3mo ago
11Jun
Purple Biotech presents IM1240 data showing 8-fold longer half-life
Purple Biotech presented new preclinical data for IM1240 at EACR 2026, showing an 8-fold longer half-life and 16-fold greater systemic exposure compared to IM1222. The CAPTN-3 masking strategy mitigated cytokine release and improved safety. Efficacy in PD-1-resistant biopsies supports a first-in-human study in 2027.
